Does Arcosa (ACA) Have the Potential to Rally 26.49% as Wall Street Analysts Expect?

Arcosa (ACA) is potentially undervalued, as the mean analyst price target of $109.20 suggests a 26.5% upside from its recent close of $86.33; however, the article cautions against relying solely on price targets due to potential biases. A more compelling indicator for upside is the recent positive trend in earnings estimate revisions, with the current year Zacks Consensus Estimate increasing by 0.4% over the last 30 days, coupled with ACA's Zacks Rank #2 (Buy).

Analysis

Arcosa (ACA) closed its last trading session at $86.33, reflecting a 2.8% gain over the preceding four weeks. Wall Street analysts project significant potential upside, with a mean short-term price target of $109.20, indicating a 26.5% increase from the current price. This average is based on five targets ranging from $100 to $120, characterized by a standard deviation of $7.29, suggesting a degree of analyst consensus. However, the article cautions against over-reliance on price targets, citing research on their questionable reliability and potential for analyst bias. Instead, it highlights a more compelling positive indicator for ACA: a favorable trend in earnings estimate revisions. Over the last 30 days, the Zacks Consensus Estimate for Arcosa's current fiscal year has risen by 0.4%, driven by one upward revision with no countervailing negative revisions. Empirical research, as noted in the article, demonstrates a strong correlation between such positive earnings estimate revisions and near-term stock price movements. Further supporting a bullish outlook, ACA currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked by this system, which has an externally-audited track record. Thus, while analyst price targets offer a directional cue, the upward trajectory of earnings estimates and the strong Zacks Rank are presented as more conclusive evidence for ACA's potential appreciation.

Key Decisions for Investors

• Investors should consider the positive trend in Arcosa's earnings estimate revisions and its Zacks Rank #2 (Buy) as primary indicators of potential near-term upside, weighing these more heavily than analyst price targets.
• While the consensus analyst price target suggests a notable 26.5% upside, this figure should be approached with a degree of skepticism, serving primarily as a point for further due diligence into the company's fundamental drivers rather than a definitive predictor of future price.
• It is advisable to monitor ongoing earnings estimate revisions and company-specific developments for ACA to continuously assess the validity of the positive earnings outlook and the strength of its underlying business fundamentals.